Immunotherapy for hormone receptor‒positive HER2-negative breast cancer by Fatima Cardoso, Kim M. Hirshfield, Kimberly A. Kraynyak, Konstantinos Tryfonidis, Aditya Bardia

Get full text

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging... by Maxwell R. Lloyd, Seth A. Wander, Erika Hamilton, Pedram Razavi, Aditya Bardia

Get full text

Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer by Neelima Vidula, Andrzej Niemierko, Katherine Hesler, Lianne Ryan, Beverly Moy, Steven Isakoff, Leif Ellisen, Dejan Juric, Aditya Bardia

Get full text

Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer by Yael Bar, Jennifer C. Keenan, Andrzej Niemierko, Arielle J. Medford, Steven J. Isakoff, Leif W. Ellisen, Aditya Bardia, Neelima Vidula

Get full text

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer by Shannon McLaughlin, Erika Nakajima, Yael Bar, Jennifer A. Hutchinson, Jennifer Shin, Beverly Moy, Steven J. Isakoff, Aditya Bardia, Irene Kuter, Laura M. Spring

Get full text

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer by Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney

Get full text

Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer by Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney

Get full text

Quality of life with ribociclib abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison by Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy, Komal Jhaveri, Sara M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A. Fasching

Get full text

Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer by Neelima Vidula, Andrew Lipman, Shumei Kato, Caroline Weipert, Katherine Hesler, Georges Azzi, Ahmed Elkhanany, Dejan Juric, Estelamari Rodriguez, Colleen Faulkner, Paul Makhlouf, Kristin Price, Joyce O’Shaughnessy, Aditya Bardia

Get full text

A careful reassessment of anthracycline use in curable breast cancer by Sara Alsterlind Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark Pegram, John P. Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon

Get full text

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer by Laura M. Spring, Shealagh L. Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J. Isakoff, Erica Mayer, Beverly Moy, Jeffrey G. Supko, Sara M. Tolaney, Aditya Bardia

Get full text

TRK inhibitor in a patient with metastatic triple-negative breast cancer and fusions identified cell-free DNA analysis by Arielle J. Medford, Lauren Oshry, Baris Boyraz, Lesli Kiedrowski, Sofia Menshikova, Anna Butusova, Charles S. Dai, Tasos Gogakos, Jennifer C. Keenan, Rachel H. Occhiogrosso, Phoebe Ryan, Jochen K. Lennerz, Laura M. Spring, Beverly Moy, Leif W. Ellisen, Aditya Bardia

Get full text

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgica... by Aditya Bardia, Lajos Pusztai, Kathy Albain, Eva Maria Ciruelos, Seock-Ah Im, Dawn Hershman, Kevin Kalinsky, Claudine Isaacs, Delphine Loirat, Laura Testa, Eriko Tokunaga, Jiong Wu, Hannah Dry, William Barlow, Robert Kozarski, Micah Maxwell, Nadia Harbeck, Priyanka Sharma

Get full text

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer by Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky

Get full text

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer by Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky

Get full text

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor... by Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, Katherine Clifton, Whitney L. Hensing, Ami N. Shah, Charles S. Dai, Carolina Reduzzi, Paolo D’Amico, Firas Wehbe, Arielle Medford, Seth A. Wander, William J. Gradishar, Amir Behdad, Fabio Puglisi, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli

Get full text

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis by Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Piccart, Yanni Zhu, Rosemary Delaney, See Phan, Javier Cortés

Get full text

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER) by Laura M. Spring, Lauren Scarpetti, Arielle J. Medford, Andrzej Niemierko, Amy Comander, Therese Mulvey, Lowell Schnipper, Steven J. Isakoff, Beverly Moy, Seth A. Wander, Jennifer Shin, Zanta Ephrem, Anneke R. Laposta, Elyssa Denault, Elizabeth Abraham, Gayle Calistro, Ekaterina Kalashnikova, Angel Rodriguez, Minetta C. Liu, Alexey Aleshin, Jeffrey Peppercorn, Leif W. Ellisen, Aditya Bardia

Get full text

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerResearch in context by Andrew A. Davis, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing, Leslie Bucheit, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, William J. Gradishar, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli

Get full text

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2− early breast cancer by Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi

Get full text